Form D · Biotechnology
bioAffinity Technologies, Inc.
San Anonio, TX · CIK 0001712762
Offering snapshot reported Oct 29, 2024 · SEC filing
- Reported sold
- $0 Offering amount: $3.99M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 21, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 29, 2024 | Initial | $0 | No comparison | 5 | SEC filing |
| Aug 12, 2024 | Initial | $1,302,084 | No comparison | 3 | SEC filing |
| Aug 12, 2024 | Initial | $450,000 | No comparison | 3 | SEC filing |
| Mar 20, 2024 | Initial | $2,624,000 | No comparison | 3 | SEC filing |
| Jul 26, 2017 | Initial | $4,047,993 | No comparison | 39 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $213K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-528041
The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement.
In connection with the offering, the placement agent received a cash placement fee equal to 8.0% of the gross proceeds received from the sale of the securities sold in the registered direct offering and the private placement among other items.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Wallachbeth Capital LLC | 000147853 |
Source: Form D, filed Oct 29, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Anderson | Director |
| Stuart Diamond | Director |
| Michael Dougherty | Executive |
| James Edwards | Executive |
| Barry Frankel | Director |
| Steven Girgenti | Director, Executive |
| Myron Holubiak | Director |
| Roby Joyce | Director |
| Peter S. Knight | Director |
| Jamie Platt | Director |
| Vivienne Rebel | Executive |
| Xavier Reveles | Executive |
| Gary Rubin | Director |
| Timothy P. Zannes | Executive |
| Maria Zannes | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3300 Nacogdoches Road Suite 216
San Anonio, TX, 78217
San Anonio, TX, 78217